Vaishali Pharma Limited (VAISHALI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vaishali Pharma Limited (VAISHALI) has a cash flow conversion efficiency ratio of 0.030x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs20.46 Million ≈ $221.23K USD) by net assets (Rs673.82 Million ≈ $7.29 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Vaishali Pharma Limited balance sheet independence to measure how much of total assets are equity-financed.
Vaishali Pharma Limited - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Vaishali Pharma Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check VAISHALI operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Vaishali Pharma Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vaishali Pharma Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Karnalyte Resources Inc.
TO:KRN
|
-0.024x |
|
Mode Tour Real Estate Investment Trust Inc
KO:204210
|
0.024x |
|
Ascendant Resources Inc
TO:ASND
|
0.017x |
|
Acme Holdings Bhd
KLSE:7131
|
0.088x |
|
Alakasa Industrindo Tbk
JK:ALKA
|
0.034x |
|
TEN Holdings, Inc. Common Stock
NASDAQ:XHLD
|
-0.663x |
|
SIXTY NORTH GOLD MIN.LTD.
F:2F40
|
-0.020x |
|
SSH GROUP LTD
F:JRSA
|
N/A |
Annual Cash Flow Conversion Efficiency for Vaishali Pharma Limited (2013–2025)
The table below shows the annual cash flow conversion efficiency of Vaishali Pharma Limited from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see Vaishali Pharma Limited market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs649.16 Million ≈ $7.02 Million |
Rs-180.38 Million ≈ $-1.95 Million |
-0.278x | -1575.62% |
| 2024-03-31 | Rs428.39 Million ≈ $4.63 Million |
Rs8.07 Million ≈ $87.24K |
0.019x | -29.31% |
| 2023-03-31 | Rs405.31 Million ≈ $4.38 Million |
Rs10.80 Million ≈ $116.77K |
0.027x | -46.76% |
| 2022-03-31 | Rs263.54 Million ≈ $2.85 Million |
Rs13.19 Million ≈ $142.60K |
0.050x | -44.23% |
| 2021-03-31 | Rs224.19 Million ≈ $2.42 Million |
Rs20.11 Million ≈ $217.49K |
0.090x | -40.41% |
| 2020-03-31 | Rs213.81 Million ≈ $2.31 Million |
Rs32.19 Million ≈ $348.11K |
0.151x | +13.11% |
| 2019-03-31 | Rs213.99 Million ≈ $2.31 Million |
Rs28.48 Million ≈ $308.01K |
0.133x | +128.99% |
| 2018-03-31 | Rs206.02 Million ≈ $2.23 Million |
Rs-94.60 Million ≈ $-1.02 Million |
-0.459x | -308.54% |
| 2017-03-31 | Rs38.69 Million ≈ $418.36K |
Rs8.52 Million ≈ $92.12K |
0.220x | -84.38% |
| 2016-03-31 | Rs32.54 Million ≈ $351.88K |
Rs45.88 Million ≈ $496.16K |
1.410x | +222.75% |
| 2015-03-31 | Rs32.35 Million ≈ $349.85K |
Rs-37.16 Million ≈ $-401.89K |
-1.149x | +49.84% |
| 2014-03-31 | Rs30.74 Million ≈ $332.40K |
Rs-70.40 Million ≈ $-761.32K |
-2.290x | -267.26% |
| 2013-03-31 | Rs27.73 Million ≈ $299.89K |
Rs37.97 Million ≈ $410.64K |
1.369x | -- |
About Vaishali Pharma Limited
Vaishali Pharma Limited engages in the pharmaceutical business in India and internationally. It offers a portfolio of active pharmaceutical ingredients, such as antibiotics, anti-ulcer, anti-inflammatory, analgesic, anti-pyretic, topical steroids, anti"malarial, cardiac, corticosteroids, anti-diabetics, anti-cold, anti-allergic, anti-diarrheal, anti-protozoal, anti-parasitic, excipients, anti-vir… Read more